1-1 of 1
Matteo Pacilli
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Dose and the duration of frontline therapy with Imatinib does not affect response to Dasatinib in Imatinib-Resistant or -intolerant patients with chronic myeloid leukemia (CML). Results from a real Life-Based Italian Multicenter retrospective study on 124 Patients.

Giuseppe Visani, Massimo Breccia, Pier Paolo Piccaluga, Antonella Gozzini, Giorgina Specchia, Enrico Montefusco, Enrica Morra, MD, Mario Annunziata, Luigiana Luciano, Andrea Camera, MD, Francesco Cavazzini, MD, Fabio Stagno, Francesco Di Raimondo, M.D., Patrizia Pregno, Francesca Pirillo, Valeria Santini, MD, Alberto Bosi, MD, Matteo Pacilli, MD, Ester Pungolino, Emilio Usala, MD, Emanuele Angelucci, MD, Monica Crugnola, Gianni Binotto, Elena Maino, Federica Loscocco, Sara Barulli, Giuseppina Nicolini, Antonio Cuneo, Roberto Latagliata, MD, Felicetto Ferrara, Alessandro Isidori, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 1124.
https://doi.org/10.1182/blood.V114.22.1124.1124
Published: 2009